Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. [electronic resource]
Producer: 19980102Description: 1523-30 p. digitalISSN:- 0002-9440
- Adenocarcinoma -- drug therapy
- Animals
- Antibodies, Monoclonal -- pharmacology
- Breast Neoplasms -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Dose-Response Relationship, Drug
- Down-Regulation -- drug effects
- Endothelial Growth Factors -- metabolism
- Epidermal Growth Factor -- immunology
- Gene Expression Regulation, Neoplastic
- Humans
- Immunoenzyme Techniques
- Lymphokines -- metabolism
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Neovascularization, Pathologic -- drug therapy
- Neutralization Tests
- Receptor, ErbB-2 -- immunology
- Signal Transduction -- physiology
- Tumor Cells, Cultured
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.